Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Hepatitis C

New therapeutic strategies needed for advanced disease

Nature Reviews Gastroenterology & Hepatology volume 6, pages 325–327 (2009)Cite this article

Approximately 50% of patients with chronic hepatitis C fail to achieve a sustained virological response to standard therapy with pegylated interferon and ribavirin. Progression to advanced liver disease (which may lead to hepatic decompensation, hepatocellular carcinoma, and death) is common in these patients, but can low-dose pegylated interferon maintenance therapy improve outcomes?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Di Bisceglie, A. M. et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N. Engl. J. Med. 359, 2429–2441 (2008).

    Article  CAS  Google Scholar 

  2. Poynard, T. et al. Impact of pegylated interferon α-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122, 1303–1313 (2002).

    Article  CAS  Google Scholar 

  3. Veldt, B. J. et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann. Intern. Med. 147, 677–684 (2007).

    Article  Google Scholar 

  4. Mallet, V. et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann. Intern. Med. 149, 399–403 (2008).

    Article  Google Scholar 

  5. Afdhal, N. H. et al. Colchicine versus PEG-interferon alfa 2b long term therapy: Results of the 4 year copilot trial. J. Hepatol. 48, S4 (2008).

    Article  Google Scholar 

  6. Poynard, T. et al. Sustained virologic response (SVR) in the EPIC3 trial: week twelve virology predicts SVR in previous interferon/ribavirin treatment failures receiving peg-intron/rebetol (PR) weight based dosing (WBD). J. Hepatol. 42, 40–41 (2005).

    Google Scholar 

  7. Papatheodoridis, G. V., Papadimitropoulos, V. C. & Hadziyannis, S. J. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment. Pharmacol. Ther. 15, 689–698 (2001).

    Article  CAS  Google Scholar 

  8. Camma, C., Giunta, M., Andreone, P. & Craxi, A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J. Hepatol. 34, 593–602 (2001).

    Article  CAS  Google Scholar 

  9. Seeff, L. B. et al. Herbal product use by persons enrolled in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 47, 605–612 (2008).

    Article  Google Scholar 

  10. Zeuzem, S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat. Clin. Pract. Gastroenterol. Hepatol. 5, 610–622 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. J. W. Goethe University Hospital, Frankfurt, Germany

    Wolf P. Hofmann & Stefan Zeuzem

Authors
  1. Wolf P. Hofmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Zeuzem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Zeuzem.

Ethics declarations

Competing interests

W. P. Hoffman is on the Speaker's bureau for Novartis and Roche. S. Zeuzem is a Consultant and is on the Speaker's bureau for Human Genome Sciences, Novartis, Roche, Schering Plough.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hofmann, W., Zeuzem, S. New therapeutic strategies needed for advanced disease. Nat Rev Gastroenterol Hepatol 6, 325–327 (2009). https://doi.org/10.1038/nrgastro.2009.63

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2009.63

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing